Retinitis Pigmentosa (RP) is a hereditary condition that groups together retinal diseases with characteristics of rod and cone dystrophy. These defects appear to cause apoptosis within the rod photoreceptors, and due to their peripheral location and functions, during childhood and mid-adulthood this leads to symptoms of night blindness with a gradually restrictive visual field and by age 40 most RP patients are registered as legally blind. In terms of management of RP, the only clinical intervention is that patients are advised to increase vitamin A levels in their diet and has been shown to slightly reduce disease progression. 1 However, at present, there appears to be no treatment for the disease or any management that appears to restore vision. Previous research has focused on gene therapy, specifically the RPE65 gene, which has received a lot of attention in the literature and seems plausible in theory especially considering that RP is a genetic disease and has shown some success in animal studies .2 The limitation of gene therapy gene therapy research is that the results may not be transferable to humans, especially considering that 45 different genes have been identified which appear to account for 60% of RP cases, with 40% of cases caused by unidentified genes3 – therefore it proves very difficult for a treatment based on gene therapy to be introduced into clinical practice due to the variability and differences between the genetic forms of retinitis pigmentosa. Considering the possible difficulties encountered with gene therapy, stem cell technology provides a promising alternative approach especially with RP. Although the etiology of the disease is not entirely clear... middle of the paper... cell research is part of the possibility of engineering stem cells into sheets for transplantation which, when considering the research, has the possibility of improving significantly improves visual function and therefore the quality of life of patients suffering from retinitis pigmentosa. In conclusion, regarding the future of retinitis pigmentosa, treatment in the form of stem cell therapy appears very promising. Even if treatment is not imminent, the next step is to apply the methods described in human studies to evaluate whether the same levels of improvement and, importantly, safety can be achieved. Although in its early stages, stem cell therapy provides a beacon of hope for those suffering from the disease as it can pave the way for both prevention of the disease and, more importantly, reversal of blindness caused by photoreceptor damage..